Tumor vascularization occurs through several distinct biological processes, which not only
vary between tumor type and anatomic location, but also occur simultaneously within the …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …

Background Outcomes in patients with Philadelphia chromosome (Ph)–positive acute
lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors …

Importance With the advent of potent BCR:: ABL1 tyrosine kinase inhibitors (TKIs),
Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) is now …

The combination of ponatinib, a third‐generation BCR:: ABL1 tyrosine kinase inhibitor, with
hyper‐CVAD chemotherapy resulted in high rates of complete molecular remissions and …

Recent major advances in understanding the molecular basis of acute myeloid leukemia
(AML) provide a double-edged sword. Although defining the topology and key features of …

Recent years have witnessed major advances that have improved outcome of adults with
acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual …

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers.
Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed …

Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL)
results in high cure rates in pediatric patients but is suboptimal in the treatment of adult …